Vanguard Global Advisers
IMRX icon

Vanguard Global Advisers’s Immuneering IMRX Stock Holding History

Vanguard Global Advisers’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Hold
24,243
– – ﹤0.01% 2697
2026
Q1 		$128K Buy
+24,243
New +$124K ﹤0.01% 2631

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Vanguard Global Advisers's IMRX Position: Q2 2026 in Review

Vanguard Global Advisers held its Immuneering (IMRX) position steady in Q2 2026 at 24,243 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #2697.

Vanguard Global Advisers first reported a position in IMRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $128K in Q1 2026. 110 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Vanguard Global Advisers held 24,243 shares of Immuneering worth $121K as of Q2 2026.
  • Vanguard Global Advisers left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2697 holding.
  • Vanguard Global Advisers first reported a position in Immuneering in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Immuneering position peaked at $128K in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.